2026-10-11T21:44:33Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34036299 2026-09-30T17:47:45Z category_7 category_8 category_12 category_13 category_14 category_19 category_39 category_46 category_61 category_64 category_132 category_134 category_135 portal_5 item_type_1 month_year_09_2026

Change in ENLIST ENL Severity Scale score from enrolment to first ENL flare requiring additional prednisolone. Barbara de Barros (12867558) Farha Sultana (24506948) Neeta Maximus (24506963) Vivek V. Pai (24506954) Anju Wakade (24506957) Bhagyashree Bhame (24506960) Bishwanath Acharya (24506951) Abdulnaser Hamza (24506942) Alemtsehay Getachew (24506945) Medhi Denisa Alinda (12867555) M. Yulianto Listiawan (24506966) Shimelis N. Doni (24506969) Deanna A. Hagge (9384569) Indra Napit (19683872) Mahesh Shah (793725) Joydeepa Darlong (683948) Peter Nicholls (155649) Bernd Genser (747128) Saba M. Lambert (24506972) Diana N. J. Lockwood (9584958) Stephen L. Walker (7879070) Medicine Microbiology Cell Biology Genetics Molecular Biology Pharmacology Ecology Immunology Developmental Biology Cancer Infectious Diseases Virology Computational Biology life improved substantially generally well tolerated affordable immunomodulatory agent adjusted hazard ratio 5 %) experienced severe inflammatory complication 62 &# 8211 differential treatment effect controlled trial conducted receive oral methotrexate week prednisolone regimen enl subsequent flares secondary outcomes related quality primary outcome participants received june 2024 january 2023 identical 20 flare frequency first flare ci 0 adverse effects 60 years 60 weeks 60 kg 54 ). 48 weeks 43 ). 40mg daily 231 individuals Change in ENLIST ENL Severity Scale score from enrolment to first ENL flare requiring additional prednisolone. 2026-09-30T17:54:41Z Image Figure 10.1371/journal.pntd.0014739.g004 https://figshare.com/articles/figure/_p_Change_in_ENLIST_ENL_Severity_Scale_score_from_enrolment_to_first_ENL_flare_requiring_additional_prednisolone_p_/34036299 CC BY 4.0